To assess long term efficacy of Omalizumab for patients with refractory chronic urticaria and angioedema

Trial Profile

To assess long term efficacy of Omalizumab for patients with refractory chronic urticaria and angioedema

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2018

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Angioedema; Urticaria
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2018 New trial record
    • 05 Mar 2018 Results presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top